Editing RareCan
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 1: | Line 1: | ||
[[File:RareCan logo.jpg|thumb|RareCan logo]] | [[File:RareCan logo.jpg|thumb|RareCan logo]] | ||
== Summary | == Summary == | ||
RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities. | RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities. | ||
Line 9: | Line 9: | ||
* Chief Technology Officer appointed | * Chief Technology Officer appointed | ||
== Idea | == Idea == | ||
<vimeo>714154182</vimeo> | <vimeo>714154182</vimeo> | ||
Line 23: | Line 23: | ||
RareCan is raising funds with the aim of growing its team, expanding its marketing and developing its platform to provide trial recruitment services to help accelerate the rate at which new treatments are made available with the aim of helping to improve outcomes for millions of people living with rare cancers. | RareCan is raising funds with the aim of growing its team, expanding its marketing and developing its platform to provide trial recruitment services to help accelerate the rate at which new treatments are made available with the aim of helping to improve outcomes for millions of people living with rare cancers. | ||
== Team | == Team == | ||
'''Mr Piers Kotting, CEO''' | '''Mr Piers Kotting, CEO''' | ||
Line 56: | Line 56: | ||
To contact RareCan, click [mailto:info@rarecan.com here]. | To contact RareCan, click [mailto:info@rarecan.com here]. | ||